TL;DR
- An Untitled Letter and a Warning Letter are both FDA advisory actions, but only one of them contains a legal threat: a Warning Letter states that failure to correct the violation may result in enforcement action, and an Untitled Letter does not (FDA, Issuance of Untitled Letters)
- FDA reserves Untitled Letters for violations that don't meet "the threshold of regulatory significance for a warning letter" — a lower tier by definition, not a softer version of the same document
- FDA is under no legal obligation to warn a firm before taking enforcement action at all, which means an Untitled Letter is a courtesy step, not a required one
- Most Untitled Letters compliance teams encounter come out of the Office of Prescription Drug Promotion, over advertising and labeling claims, not manufacturing (CGMP) findings
- Getting this distinction wrong in an internal risk register means either over-escalating a minor labeling note or under-reacting to a document that, on its face, already carries FDA's most serious warning
What's the actual difference between an FDA Untitled Letter and a Warning Letter?
Treat them as the same letter with different letterhead, and the mistake compounds. An Untitled Letter cites violations FDA has already decided fall below "the threshold of regulatory significance" that would justify a Warning Letter (FDA, Issuance of Untitled Letters). That's not FDA being polite. That's FDA telling you, in the agency's own classification system, which tier your violation landed in before you opened the envelope.
The one sentence that actually separates them: a Warning Letter states that failure to promptly correct the violation may result in enforcement action. An Untitled Letter omits that sentence entirely.
Why does FDA even bother with a lower tier?
FDA's own compliance framework treats letters as one tool among several for securing voluntary correction before resorting to formal action — seizure, injunction, or prosecution. Not every deviation from the Federal Food, Drug, and Cosmetic Act is severe enough to warrant opening that door. The agency is under no legal obligation to warn a firm at all before enforcing; issuing any letter, untitled or not, is discretionary. Read that against the plain language of the Regulatory Procedures Manual's own advisory-actions framework, and the two-tier system looks less like agency courtesy and more like triage: reserve the formal threat for violations FDA is actually prepared to act on next.
That triage logic is why a firm can receive an Untitled Letter over an advertising claim and never hear from FDA again, while another firm gets a Warning Letter over the same category of claim and finds itself facing a follow-up inspection eighteen months later. The letter type isn't cosmetic. It's FDA pre-announcing its own next move, or the absence of one.
Where compliance teams actually run into this
Most Untitled Letters in the drug space come from the Office of Prescription Drug Promotion (OPDP), addressing promotional claims, off-label messaging, or missing risk information in advertising — not the CGMP manufacturing citations that dominate Warning Letters. Argus HQ has already covered a live example of this exact split: FDA sent Novo Nordisk both a Warning Letter over pharmacovigilance reporting failures and a separate, less severe OPDP Untitled Letter over a Wegovy TV ad, in the same enforcement window (Argus HQ: Why did the FDA send Novo Nordisk a warning letter). Same company, same quarter, two different tiers of FDA response — because the two problems weren't equally serious in FDA's own accounting.
| Untitled Letter | Warning Letter | |
|---|---|---|
| Violation severity | Below the threshold of regulatory significance | Meets the threshold of regulatory significance |
| Enforcement warning included | No | Yes — states action may follow if uncorrected |
| Legally required before enforcement | No — FDA can enforce without any prior letter | No — same discretionary basis |
| Typical drug-space source | OPDP (advertising/promotion) | CDER/CBER field offices (CGMP, data integrity) |
| Public posting | Posted to Center website when FOIA-request volume or public-health interest justifies it, usually within 10 workdays | Posted to FDA's searchable Warning Letter database |
| Close-out letter available | No formal close-out program | Yes, once corrective action is verified, usually via follow-up inspection |
Sources: FDA, Issuance of Untitled Letters; FDA, About Warning and Close-Out Letters
What should a compliance team do differently based on which letter arrives?
- Don't downgrade an Untitled Letter to "no action needed." FDA still expects prompt correction — it just hasn't invoked the enforcement threat yet. Waiting it out is a bet that FDA's tolerance stays where it is.
- Don't treat a Warning Letter as negotiable in tone. By the time that sentence about enforcement action appears, FDA has already concluded the violation clears its own significance bar. That's not an opening position — see how FDA evaluates whether a company's response actually closes the matter out (Argus HQ: what makes a warning letter response adequate).
- Check which office sent it. An OPDP Untitled Letter over ad copy calls for a marketing/regulatory-affairs fix. A field-office Warning Letter over CGMP calls for a quality-system investigation. Routing the wrong team at the wrong document wastes the response window either way.
- Log both documents, but don't average their severity. A firm with one Untitled Letter and one Warning Letter on file in the same year isn't "moderately" risky — it has one closed, lower-tier matter and one live, formally warned matter that FDA is watching for a follow-up inspection.
FAQ
Is an Untitled Letter a warning that enforcement is coming?
No. That's the specific sentence FDA leaves out of an Untitled Letter. It cites a violation and requests correction, but it does not warn that enforcement action may follow if the firm fails to act (FDA, Issuance of Untitled Letters).
Can an Untitled Letter turn into a Warning Letter?
FDA doesn't formally "escalate" one document into the other, but if the underlying violation continues or a related, more significant violation surfaces later, a subsequent Warning Letter can follow. The two are separate agency decisions, not sequential drafts of the same letter.
Are Untitled Letters public the same way Warning Letters are?
Not identically. FDA posts an Untitled Letter to a Center website only when it meets specific criteria — enough anticipated FOIA requests, a public-health information interest, or a deterrence rationale — normally within 10 workdays of that decision. Warning Letters go straight into FDA's searchable public database as a matter of course.
Which office sends most drug-related Untitled Letters?
The Office of Prescription Drug Promotion (OPDP) issues the bulk of Untitled Letters compliance teams see in the drug space, almost always over advertising, labeling, or promotional-claims issues rather than manufacturing.
Why compliance teams pick Argus over building this tracking in-house →
Sources: FDA, Issuance of Untitled Letters, FDA, About Warning and Close-Out Letters. Byline: The Argus Regulatory Analysis Team. Published 2026-07-10.